医療関係者様へ

2024年発表論文

2024.03.01

2024年に当教室で発表した和文論文です。

題名（論文名）	著者	掲載雑誌
63歳男性の会陰部に発生した侵襲性血管粘液腫の一例	新澤玲、門本卓、牧野友幸、内藤伶奈人、岩本大旭、八重樫洋、川口昌平、重原一慶、野原隆弘、泉浩二、角野佳史、　溝上敦	泌尿器外科2024; 37(2): 174-179.
TUL に伴う医原性右尿管損傷に対し、虫垂利用尿管置換術を施行した一例	新澤玲、野原隆弘、八重樫洋、泉浩二、加藤晴朗、溝上敦	臨床泌尿器科2024; 78(9): 703-708.
男性不妊患者を対象とした精液、尿、亀頭擦過検体における HPV-DNA 検出率の比較	新澤玲、重原一慶、中川朋美、加藤佑樹、中嶋一史、川口昌平、溝上敦	日本性感染症学会雑誌2024; 35(1): 7-12.
HCG異常持続するも手術により寛解を得たgrowing teratoma syndromeの1例	高田真吾, 八重樫洋, 内藤伶奈人, 牧野友幸, 岩本大旭, 川口昌平, 重原一慶, 野原隆弘, 泉浩二, 池田博子, 溝上敦	日本泌尿器科学会雑誌2024; 115(4): 189-192
感染症最新の治療2025-2027．性器クラミジア感染症．	重原一慶	南江堂，東京，2024．
【臨床腎・泌尿器癌(中)-基礎・臨床研究の進歩-】膀胱癌の治療　手術療法　経尿道的膀胱腫瘍切除術　光力学診断を併用したTURBT　有害事象	野原隆弘、溝上敦	日本臨床2024; 82(9); 165-171.
【ロボット支援手術におけるNightmareとその対策】こんなときにロボットが止まったら…一歩間違えば一大事という経験2例から得た教訓	野原隆弘, 瀬戸親, 溝上敦	Japanese Journal of Endourology and Robotics 2024; 37(9): 282-289.
腫瘍マーカー　使い方のコツとピットフォール(No.9)　前立腺神経内分泌がん(ProGRP,NSE)	岩本大旭, 溝上敦	日本医師会雑誌2024; 153(4): 442-443.
【進行性泌尿器科癌の一次全身治療　争論!クロスファイア2024】High risk(High volume) mCapに対する一次全身治療　mCSPCに対するホルモン療法　ADT(CAB)で十分	溝上敦	泌尿器外科2024; 37(4): 309-314.

2024年に当教室の医局員がfirst authorで発表した英文論文です。

題名（論文名）	著者	掲載雑誌
Comparing ceftolozane/tazobactam versus piperacillin/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study.	Nakagawa T, Shigehara K, Shinzawa R, Yaegashi H, Kawaguchi S, Nohara T, Izumi K, Mizokami A.	J Infect Chemother. 2024 ;30(1):12-16.
Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?	Nakagawa R, Izumi K, Toriumi R, Aoyama S, Kamijima T, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	Int J Urol. 2024; 31(6):628-636.
Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer.	Kano H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	Biomedicines 2024; 12(2):292.
Procalcitonin in advanced urological cancer-bacterial versus non-bacterial infections: prospective cohort study.	Yaegashi H, Izumi K, Toriumi R, Aoyama S, Kamijima T, Kano H, Makino T, Naito R, Iwamoto H, Kawaguchi S, Nohara T, Shigehara K, Mizokami A.	BMJ Support Palliat Care. 2024 :spcare-2023-004758.
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa	Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A.	Cancers (Basel). 2024;16(3):508.
Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?	Nakagawa R, Nohara T, Kano H, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Mizokami A.	Photodiagnosis Photodyn Ther. 2024; 46:104023.
Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.	Nohara T, Takimoto A, Shinzawa R, Kurauchi D, Toriumi R, Nakagawa R, Aoyama S, Kamijima T, Kano H, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Mizokami A.	Int J Urol. 2024 31(8):891-898.
A seed link connector protruding into the bladder formed a bladder stone.	Aoyama S, Izumi K, Makino T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	IJU Case Rep. 2024;7(2):188-191.
Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy.	Kano H, Kadono Y, Naito R, Makino T, Iwamoto H, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Mizokami A.	Cancers (Basel). 2024; 16(7):1304.
Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.	Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Mizokami A.	Cancers (Basel). 2024; 16(18):3198.
Therapeutic efficacy and safety ofweekly administration of enfortumab vedotin for urothelial carcinoma.	Nakagawa R, Izumi K, Toriumi R, Aoyama S, Kamijima T, Kano H, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	Jpn J Clin Oncol. 2024; 54(12):1329-1335.
Comparison of dutasteride efficacy among the patients with small versus large benign prostatic hypertrophy.	Shigehara K, Kato Y, Kawaguchi K, Izumi K, Kadono Y, Mizokami A.	Curr Urol. 2024;18(3):199-202.
Microsatellite Instability-High and High Tumor Mutation Burden Frequencies in Urologic Malignancies Off-Label for Immune Checkpoint Inhibitors in Japan: A Retrospective Single-Institutional Cohort.	Yaegashi H, Izumi K, Makino T, Naito R, Iwamoto H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	Cureus. 2024; 16(9):e69366.
Real-world short-term outcomes of prostate urethral lift in Japan: A prospective cohort study.	Kato Y, Kamatani A, Shigehara K, Mizokami A.	Int J Urol. 2024; 31(8):852-858.
Identification of uromodulin deposition in the stroma of perinephric fibromyxoid nephrogenic adenoma by mass spectrometry.	Yoshimura K, Ito Y, Suzuki M, Horie M, Nishiuchi T, Shintani-Domoto Y, Shigehara K, Oshima H, Oshima M, Goto A, Nojima T, Tsuzuki T, Mizokami A, Ikeda H, Maeda D.	Pathol Int. 2024; 74(4):187-196.
Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.	Iwamoto H, Izumi K, Mizokami A.	Transl Androl Urol. 2024; 13(7):1324-1326.
Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer	Inaki A, Mizokami A, Wakabayashi H, Izumi K, Kadono Y, Toyama T, Takahara S, Murayama T, Kinuya S.	Ann Nucl Med. 2024; 38(8):587-595.

一覧に戻る